9622 Federal Register / Vol. 87, No. 35 / Tuesday, February 22, 2022 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund the 

Kazakhstan Scientific Center for 

Dermatology and Infectious Diseases 

(KSCDID) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $500,000, for 

Year 1 of funding to the Kazakhstan 

Scientific Center for Dermatology and 

Infectious Diseases (KSCDID). The 

award will reduce new HIV infections 

and AIDS deaths in Kazakhstan through 

rapidly expanding prevention, testing, 

care, and effective treatment services to 

people living with HIV (PLHIV). 

Funding amounts for years 2–5 will be 

set at continuation. 

DATES: The period for this award will be 

September 30, 2022 through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Patrick Nadol, Center for Global Health, 

Centers for Disease Control and 

Prevention, 171 Prospect Mira, Bishkek, 

720016, Kyrgyz Republic, Telephone: 

800–232–6348, E-Mail: pen5@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will implement 

prevention, testing, care and treatment, 

laboratory, and strategic information 

activities in Kazakhstan. KSCDID is in a 

unique position to conduct this work, as 

it is the leading organization 

implementing the National HIV program 

in Kazakhstan; it will lead and sustain 

the national HIV services for prevention, 

testing, care, treatment, and strategic 

information according to international 

standards to achieve epidemic control 

and ensure resilient and sustained 

health care systems. KSCDID develops 

policy and regulations, conducts 

prevention and testing activities, 

coordinates care and treatment, and is 

responsible for quality assurance of 

laboratory services. 

Summary of the Award 

Recipient: Kazakhstan Scientific 

Center for Dermatology and Infectious 

Diseases (KSCDID). 

Purpose of the Award: The purpose of 

this award is to reduce new HIV 

infections and AIDS deaths in 

Kazakhstan through rapidly expanding 

prevention, testing, care, and effective 

treatment services to PLHIV. 

Amount of Award: The approximate 

year 1 funding amount will be $500,000 

in Federal Fiscal Year (FFY) 2022 funds, 

subject to the availability of funds. 

Funding amounts for years 2–5 will be 

set at continuation. 

Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003). 

Period of Performance: September 30, 

2022 through September 29, 2027. 

Dated: February 15, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–03629 Filed 2–18–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–22–1268] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Drug Overdose 

Surveillance and Epidemiology (DOSE)’’ 

to the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on April 26, 2021, to obtain 

comments from the public and affected 

agencies. CDC received four comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Drug Overdose Surveillance and 

Epidemiology (DOSE) (OMB Control No. 

0920–1268, Exp. 8/31/2022)— 

Revision—National Center for Injury 

Prevention and Control (NCIPC), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

In 2020, a total of 91,799 drug 

overdose deaths occurred, 

corresponding to an age-adjusted rate of 

28.3 per 100,000 population and a 31% 

increase from the 2019 rate (21.6). From 

2013 to 2019, the synthetic opioidinvolved death rate increased 1,040%, 

from 1.0 to 11.4 per 100,000 ageadjusted (3,105 to 36,359). The 

psychostimulant-involved death rate 

increased 317%, from 1.2 (3,627) in 

2013 to 5.0 (16,167) in 2019. Non-fatal 

overdoses are on the rise as well; 

Emergency Department (ED) data from 

DOSE indicates increases from 2018 to 

present. In response to the growing 

severity of the opioid overdose 

epidemic, the U.S. government declared 

the opioid overdose epidemic a public 

health emergency on October 26, 2017. 

The opioid overdose epidemic is one of 

the top priorities of the U.S. Department 

of Health and Human Services (HHS). In 


lotter on DSK11XQN23PROD with NOTICES1